Core Insights - The technology and manufacturing, as well as healthcare sectors, are solidifying their positions as the dual core of investment activity, with significant financing cases concentrated in these areas [1] - The past two weeks have seen a surge in financing activities, particularly in embodied intelligence, new drug development, and advanced manufacturing [1][2] Financing Overview - A total of 23 financing events were disclosed in the domestic primary market from February 9 to February 23, 2026, with a total financing scale exceeding 38.09 billion RMB [2] - The healthcare sector completed 12 financing rounds amounting to approximately 24.44 billion RMB, while the technology and manufacturing sector completed 10 rounds totaling about 12.65 billion RMB [4] Sector Distribution - The financing distribution shows that the technology and manufacturing sector had 10 cases with a disclosed amount of approximately 12.65 billion RMB, while the healthcare sector had 12 cases with about 24.44 billion RMB [4] - The consumer services sector had only 1 case with a disclosed amount of 1 billion RMB [4] Regional Distribution - The financing activities were primarily concentrated in Shanghai, Guangdong, Beijing, Jiangsu, and Zhejiang, with Shanghai leading with 8 cases [5] Active Investment Institutions - Hillhouse Capital was notably active, completing 3 financing rounds primarily in the healthcare sector [6] Notable Financing Cases - Shanghai Yuesai Biotechnology completed a new round of financing of 50 million RMB on February 11, 2026, focusing on stem cell therapy [7] - Supervision completed over 100 million RMB in B+ round financing on February 10, 2026, for advanced imaging systems [8] - Ice Crystal Intelligent completed several million RMB in A+ round financing on February 10, 2026, focusing on cardiac intervention devices [9] - Huixin Biotechnology completed nearly 100 million RMB in A+ round financing on February 10, 2026, for exosome purification and cancer early detection [10] - Regend Therapeutics completed 350 million RMB in C round financing on February 11, 2026, focusing on regenerative medicine [11] - Beijing Zhiren Medical Technology completed 300 million RMB in A+ round financing on February 11, 2026, for brain-machine interface technology [12] - KSKD completed nearly 500 million RMB in a new round of financing on February 10, 2026, focusing on original drug development [13] - AGILINK completed several hundred million RMB in A round financing on February 11, 2026, focusing on robotic end-effectors [14] - Juwei Technology completed over 100 million RMB in A+ round financing on February 11, 2026, focusing on embodied intelligence technology [15] - Baier New Materials completed 65 million RMB in B round financing on February 11, 2026, focusing on 3D printing electronic materials [16] - INFLYNC completed over 100 million RMB in A round financing on February 11, 2026, focusing on eVTOL aircraft [18] - Xinghai Map completed 1 billion RMB in B round financing on February 11, 2026, focusing on embodied intelligence services [19] - Krey Technology completed over 100 million RMB in B round financing on February 11, 2026, focusing on micro-motor production [20] - Qunche Intelligent completed several million RMB in angel round financing on February 10, 2026, focusing on embodied intelligence technology [21]

Core Insights - The dual-core pattern of technology and manufacturing, along with healthcare, is further solidified, with these two sectors dominating the majority of financing cases this week. Significant financing rounds of over 100 million RMB are concentrated in fields such as embodied intelligence, new drug development, and high-end manufacturing, with leading investment institutions continuing to increase their investments in hard technology and medical innovation [1] Group 1: Financing Trends - In the past two weeks, the technology and manufacturing sectors have led the market with multiple financing rounds, maintaining a core position in financing. Companies like Juwei Technology and Keli Technology have completed financing rounds exceeding 100 million RMB [1][4] - The healthcare sector has seen a surge in financing, with a focus on AI-enabled medical solutions and innovative biotherapies. Companies such as Beijing Zhiran Medical Technology and Bingjing Intelligent have secured significant funding [1][4] Group 2: Sector Performance - In the three major sectors, the technology and manufacturing sector completed 10 financing rounds totaling approximately 12.65 billion RMB, while the healthcare sector completed 12 financing rounds with disclosed amounts of about 24.44 billion RMB [4][5] - The consumer services sector completed only 1 financing round with a disclosed amount of 1 billion RMB [4] Group 3: Regional Distribution - The financing activities in the past two weeks were primarily concentrated in Shanghai, Guangdong, Beijing, Jiangsu, and Zhejiang, with Shanghai leading with 8 financing rounds [6][7] Group 4: Active Investment Institutions - Hillhouse Capital has been notably active in the past two weeks, completing 3 financing rounds primarily focused on the healthcare sector [8] Group 5: Company-Specific Financing - Yuesai Biotechnology completed a new round of financing amounting to 50 million RMB, focusing on stem cell therapy [9] - Chaowei Jing completed over 100 million RMB in B+ round financing, specializing in advanced imaging systems [10] - Bingjing Intelligent secured several million RMB in A+ round financing, targeting structural heart disease and electrophysiology markets [11] - Huixin Biotechnology raised nearly 100 million RMB in A+ round financing, focusing on exosome purification and early cancer detection [12] - Jimei Life Sciences completed 350 million RMB in C round financing, specializing in regenerative medicine [13] - Beijing Zhiran Medical Technology announced 300 million RMB in A+ round financing, focusing on invasive brain-machine interfaces [14] - Kaisi Kedi completed nearly 500 million RMB in a new financing round, focusing on original drug development [15] - Limiting Point completed several hundred million RMB in financing, specializing in embodied intelligence robotics [16] - Juwei Technology completed over 100 million RMB in A+ round financing, focusing on embodied intelligence technology [18] - Baierou New Materials completed 65 million RMB in B round financing, focusing on 3D printing electronic functional materials [19] - INFLYNC Tianling Technology completed over 100 million RMB in A round financing, focusing on eVTOL aircraft design and manufacturing [20] - Xinghai Map completed 1 billion RMB in B round financing, focusing on embodied intelligence products [21] - Keli Technology completed over 100 million RMB in B round financing, specializing in micro-motor production [22] - Qiongche Intelligent completed several million RMB in angel round financing, focusing on embodied intelligence technology [23]